RE:RE:RE:RE:Durability, Durability, Durability#ASH22: 'Not so surprising': With lack of durability, Affimed scraps monotherapy plans in favor of NK cell combo.
Affimed won’t move ahead with an accelerated approval application for its drug AFM13, an innate cell engager it was testing in relapsed/refractory peripheral T-cell lymphoma, after a lackluster trial result.
https://endpts.com/ash22-not-so-surprising-with-lack-of-durability-affimed-scraps-monotherapy-plans-in-favor-of-nk-cell-combo/